Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified a sulfotransferase activity in rat liver that catalyzes the sulfation of minoxidil, contributing to its delayed hypotensive effects.

This study reports the purification of a specific sulphotransferase from rat liver that catalyzes the sulphation of minoxidil, potentially implicating it in minoxidil's bioactivation.

Minoxidil works in liver and outer hair root sheath for hair growth.

In this study, researchers found that both thermolabile and thermostable forms of phenol sulfotransferase contribute to the sulfation of minoxidil, emphasizing the need to consider both enzymes in assessing sulfation in human tissues.

This study found that minoxidil is bioactivated through sulfation by the phenol-sulfating form of phenol sulfotransferase in human liver.

This study found that human liver dehydroepiandrosterone sulfotransferase (DHEA ST) catalyzes the sulfate conjugation of minoxidil, indicating another pathway contributing to its metabolism in humans.

Human platelets change minoxidil to minoxidil sulfate, helping blood vessels widen.

This study suggests that rat skin may synthesize minoxidil sulphate independently, implying the skin could contribute to minoxidil's hair growth promotion without help from the liver or other organs.

In this review, the authors report that topical minoxidil effectively stimulates hair growth in androgenic alopecia and to a lesser extent in nasal alopecia, particularly in early stages, with minimal and typically short-lived adverse skin reactions, but no systemic side effects.

This study found that at least four different human sulfotransferase activities contribute to the sulfation of minoxidil, complicating predictions of individual responses based on ST levels.

This review discusses recent molecular biology advances in the human phenol sulfotransferase gene family and reports no new results; the authors highlight its relevance for studies of endogenous and xenobiotic metabolism.

This article discusses the role of Minoxidil Sulfotransferase Enzyme (SULT1A1) genetic variants in predicting the response to oral minoxidil for treating female pattern hair loss, without presenting new research findings.

This paper introduces a novel topical booster aimed at enhancing follicular sulfotransferase activity to potentially improve minoxidil response in patients with androgenetic alopecia but reports no new clinical results.

Human enzymes can detoxify harmful substances but might also increase their cancer risk.

Minoxidil activation by hair enzymes predicts treatment success for female hair loss.

Food deprivation increases MST enzyme in the brain, possibly affecting energy balance.

This study reported that sulfotransferase activity in plucked hair follicles can predict treatment response to 5% topical minoxidil in women with androgenetic alopecia with high sensitivity and specificity.

In this study of Indian patients with pattern hair loss, 40.8% showed low sulfotransferase enzyme activity in hair follicles, with a higher prevalence of low activity in men compared to women.

This review discusses the potential of using SULT1A1 expression in the scalp as a biomarker to predict response to minoxidil treatment for androgenetic alopecia, but reports no new clinical results.

This study found that 63.4% of androgenetic alopecia patients showed clinical improvement after 6 months of low-dose oral minoxidil, with patients having low sulfotransferase activity in hair follicles responding more favorably than those with high enzyme activity.

In this study, scalp skin from stumptailed macaques demonstrated minoxidil sulfotransferase activity primarily in hair follicles, which may explain minoxidil's hair growth stimulation in this model.

This study found that 14 days of low-dose aspirin reduced the predicted response to topical minoxidil in androgenetic alopecia patients from 50% to 27%, suggesting aspirin may inhibit minoxidil efficacy.

This study characterized the activity of naturally occurring minoxidil sulfotransferase enzymes in various plants and found that seven out of ten botanical extracts showed significant activity, suggesting these could potentially enhance minoxidil response in treating androgenetic alopecia.

This study reports a method for efficiently synthesizing chromeno-pyrimidine-N-oxides in good to excellent yields, confirmed by X-ray analysis, through a reaction between 4-chloro-3-formylcoumarin and aromatic carboximide oximes.

This review discusses the preclinical findings on cyproterone acetate and suggests that while it has a low potential cancer risk for patients, its tumor effects in female rats may involve both genotoxic and mitogenic mechanisms.

This study suggests that a hair follicle enzyme assay may predict response to minoxidil treatment for androgenetic alopecia with high sensitivity and specificity in a preliminary analysis.

This article discusses female pattern baldness and effective treatments like oral anti-androgens and topical minoxidil for managing its progression and reversing hair follicle shrinkage, but reports no new findings.

This review discusses the research supporting the approval and use of minoxidil for androgenic alopecia and reports no new clinical results, emphasizing recent findings and developments.

This study found that incorporating 0.5% TPGS into topical minoxidil solutions enhanced hair growth in mice, although increasing TPGS to 2% decreased effectiveness.

This case report presented by the authors provides the first evidence of severe liver failure associated with the use of topical minoxidil, emphasizing the potential for hepatotoxicity even from drugs with minimal systemic absorption.